Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro
Thomas Mohr, Lucia Desser, Thomas Mohr, Lucia Desser
Abstract
Background: Vascular endothelial growth factor (VEGF) is a key regulator of physiologic and pathogenic angiogenesis in diseases such as cancer and diabetic retinopathy. It is known that cysteine proteases from plants, like bromelain and papain are capable to suppress inflammatory activation. Recent studies have demonstrated that they may interfere with angiogenesis related pathways as well. The aim of this study was to investigate the anti-angiogenic effects of papain on human umbilical vein endothelial cells (HUVEC) in vitro.
Methods: Cell viability after prolonged treatment with papain was investigated by life cell staining and lactate dehydrogenase release assay. Angiogenic activation was assessed by ELISA against phosphorylated proteins AKT, MEK1/2, ERK1/2, SAPK/JNK and p38-MAPK. Growth inhibition was determined by means of an MTT-assay and cell migration by means of a scratch assay. Capability to form a capillary network was investigated using a tube formation assay.
Results: Papain did not induce proteolysis or cell detachment of HUVEC in a concentration range between 0 and 25 μg/mL. Four hours treatment with 10 μg/mL papain resulted in a reduced susceptibility of endothelial cells to activation by VEGF as determined by phosphorylation levels of Akt, MEK1/2, SAPK/JNK. Papain exerted a distinct inhibitory effect on cell growth, cell migration and tube formation with inhibition of tube formation detectable at concentrations as low as 1 μg/mL. Bromelain and ficin displayed similar effects with regard to cell growth and tube formation.
Conclusion: Papain showed a strong anti-angiogenic effect in VEGF activated HUVEC. This effect may be due to interference with AKT, MEK1/2 and SAPK/JNK phosphorylation. Two other plant derived cysteine proteases displayed similar inhibition of HUVEC cell growth and tube formation. These findings indicate that plant proteolytic enzymes may have potential as preventive and therapeutic agents against angiogenesis related human diseases.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3849051/bin/1472-6882-13-231-1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3849051/bin/1472-6882-13-231-2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3849051/bin/1472-6882-13-231-3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3849051/bin/1472-6882-13-231-4.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3849051/bin/1472-6882-13-231-5.jpg)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3849051/bin/1472-6882-13-231-6.jpg)
References
- Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. doi: 10.1038/35025220.
- Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58–61. doi: 10.1038/339058a0.
- Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol. 2007;62:105–118. doi: 10.1016/j.critrevonc.2006.11.006.
- Jacobs J. Combating cardiovascular disease with angiogenic therapy. Drug Discov Today. 2007;12:1040–1045. doi: 10.1016/j.drudis.2007.08.018.
- Khurana R, Simons M, Martin JF, Zachary IC. Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal. Circulation. 2005;112:1813–1824. doi: 10.1161/CIRCULATIONAHA.105.535294.
- Moulton KS. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol. 2006;17:548–555. doi: 10.1097/01.mol.0000245261.71129.f0.
- Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464–478. doi: 10.1038/nrm2183.
- Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437:169–183. doi: 10.1042/BJ20110301.
- Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001;58:1234–1245. doi: 10.1007/PL00000936.
- Chobotova K, Vernallis A, Majid F. Bromelain’s activity and potential as an anti-cancer agent: Current evidence and perspectives. Cancer Lett. 2010;290:148–156. doi: 10.1016/j.canlet.2009.08.001.
- Majima M, Nishiyama K, Iguchi Y, Yao K, Ogino M, Ohno T, Sunahara N, Katoh K, Tatemichi N, Takei Y, Katori M. Determination of bradykinin-(1–5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm Res. 1996;45:416–423. doi: 10.1007/BF02252938.
- Ogino M, Majima M, Kawamura M, Hatanaka K, Saito M, Harada Y, Katori M. Increased migration of neutrophils to granulocyte-colony stimulating factor in rat carrageenin-induced pleurisy: roles of complement, bradykinin, and inducible cyclooxygenase-2. Inflamm Res. 1996;45:335–346. doi: 10.1007/BF02252946.
- Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti- inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung. 2000;50:728–738.
- Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee–a double-blind prospective randomized study. Clin Rheumatol. 2004;23:410–415. doi: 10.1007/s10067-004-0902-y.
- Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. Fortschr Med. 1995;113:303–306.
- Inoue K, Motonaga A, Dainaka J, Nishimura T, Hashii H, Yamate K, Ueda F, Kimura K. Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation. Prostaglandins Leukot Essent Fatty Acids. 1994;51:457–462. doi: 10.1016/0952-3278(94)90065-5.
- Eckert K, Grabowska E, Stange R, Schneider U, Eschmann K, Maurer HR. Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol Rep. 1999;6:1191–1199.
- Hale LP, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol. 1992;149:3809–3816.
- Munzig E, Eckert K, Harrach T, Graf H, Maurer HR. Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett. 1994;351:215–218. doi: 10.1016/0014-5793(94)00860-4.
- Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol. 2002;104:183–190. doi: 10.1006/clim.2002.5254.
- Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett. 2009;282:167–176. doi: 10.1016/j.canlet.2009.03.003.
- Kalra N, Bhui K, Roy P, Srivastava S, George J, Prasad S, Shukla Y. Regulation of p53, nuclear factor κB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicol Appl Pharmacol. 2008;226:30–37. doi: 10.1016/j.taap.2007.08.012.
- Bhui K, Tyagi S, Srivastava AK, Singh M, Roy P, Singh R, Shukla Y. Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G(2)/M arrest to apoptosis. Mol Carcinog. 2012;51:231–243. doi: 10.1002/mc.20769.
- Hou RC-W, Chen Y-S, Huang J-R, Jeng K-CG. Cross-Linked Bromelain Inhibits Lipopolysaccharide-Induced Cytokine Production Involving Cellular Signaling Suppression in Rats. J Agric Food Chem. 2006;54:2193–2198. doi: 10.1021/jf052390k.
- Gebäck T, Schulz MMP, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 2009;46:265–274.
- Guidolin D, Albertin G, Ribatti D. In: Microscopy: Science, Technology, Applications and Education, Volume 2. Méndez-Vilas A, Diaz J, editor. Badajoz, Spain: Formatex; 2010. Exploring in vitro angiogenesis by image analysis and mathematical modeling; pp. 876–884.
- Lamprecht MR, Sabatini DM, Carpenter AE. Cell Profiler: free, versatile software for automated biological image analysis. Biotechniques. 2007;42:71–75. doi: 10.2144/000112257.
- Otsu N. A threshold selection method from gray-level histograms. Automatica. 1975;11:285–296. doi: 10.1016/0005-1098(75)90044-8.
- Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, Evangelisti C. The emerging multiple roles of nuclear Akt. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2012;1823:2168–2178. doi: 10.1016/j.bbamcr.2012.08.017.
- Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, Larouche L, Rousseau S, Huot J, Landry J, Jeannotte L, Charron J. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol. 1999;9:369–372. doi: 10.1016/S0960-9822(99)80164-X.
- Berra E, Milanini J, Richard DE, Le Gall M, Viñals F, Gothié E, Roux D, Pagès G, Pouysségur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol. 2000;60:1171–1178. doi: 10.1016/S0006-2952(00)00423-8.
- Dong G, Chen Z, Li Z-Y, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte Growth Factor/Scatter Factor-induced Activation of MEK and PI3K Signal Pathways Contributes to Expression of Proangiogenic Cytokines Interleukin-8 and Vascular Endothelial Growth Factor in Head and Neck Squamous Cell Carcinoma. Cancer Res. 2001;61:5911–5918.
- Huang D, Ding Y, Luo W-M, Bender S, Qian C-N, Kort E, Zhang Z-F, VandenBeldt K, Duesbery NS, Resau JH, Teh BT. Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo. Cancer Res. 2008;68:81–88. doi: 10.1158/0008-5472.CAN-07-5311.
- Mynott TL, Ladhams A, Scarmato P, Engwerda CR. Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J Immunol. 1999;163:2568–75.
- Issbrücker K, Marti HH, Hippenstiel S, Springmann G, Voswinckel R, Gaumann A, Breier G, Drexler HCA, Suttorp N, Clauss M. p38 MAP kinase-a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 2003;17:262–264.
- Wagner EF, Nebreda ÁR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–549. doi: 10.1038/nrc2694.
- Boyd PJ, Doyle J, Gee E, Pallan S, Haas TL. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol. 2005;288:C659–C668.
- Uchida C, Gee E, Ispanovic E, Haas T. JNK as a positive regulator of angiogenic potential in endothelial cells. Cell Biol Int. 2008;32:769–776. doi: 10.1016/j.cellbi.2008.03.005.
- McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells. J Biol Chem. 2005;280:20995–21003. doi: 10.1074/jbc.M407060200.
- Rajashekhar G, Kamocka M, Marin A, Suckow MA, Wolter WR, Badve S, Sanjeevaiah AR, Pumiglia K, Rosen E, Clauss M. Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. J Cell Physiol. 2011;226:800–808. doi: 10.1002/jcp.22404.
Source: PubMed